Reiferon Retard

Quick links

Choose a section

Quick links to important sections

Advertisements

Reiferon Retard

Advertisements
Advertisements

Overview of Reiferon Retard

Quick Facts

Property Description
Active ingredient Peginterferon Alfa 2-a
Form Aqueous solution for injection
Pharmacological class Type I Interferon, Cytokine
General purpose Immunostimulant and antiviral agent
Origin Biologic, manufactured using recombinant DNA technology

What Type of Medicine is Peginterferon Alfa 2-a?

Reiferon Retard is defined by its active ingredient, Peginterferon Alfa 2-a, which belongs to the class of Type I Interferons. This medication is fundamentally a biologic agent, classified as a Cytokine and a Biological Response Modifier, meaning it works by modulating the body's natural immune and cellular processes. Its classification as an immunostimulant and antiviral agent defines its general role in regulating the immune system to combat long-term viral issues. The substance is categorized as a member of the Interferon class, which is crucial for initiating the host defense against viruses. The medication functions by activating and supporting the body's primary viral-fighting capabilities, a mechanism employed in chronic infections.

Composition and Form: The Role of Pegylation

The chemical identity of the active ingredient is a modified protein; Peginterferon Alfa 2-a is a covalent conjugate of the Interferon Alfa-2a protein and a Polyethylene Glycol (PEG) chain. This structural modification, known as pegylation, is performed to create a long-acting preparation. Pegylation significantly extends the drug's half-life in the bloodstream, enabling less frequent dosing. This modification provides the practical benefit of a more stable drug concentration and simplified administration schedule. The drug is supplied as a sterile aqueous solution for injection, and the administration route is subcutaneous, facilitating its slow and sustained absorption into the circulation.

General Purpose and Antiviral Function

The overarching purpose of this medication is to help the body mount a potent and continuous defense against viral pathogens. The Peginterferon Alfa 2-a molecule functions by signaling to cells to heighten their readiness, thereby establishing a cellular environment that inhibits viral replication. The extended half-life afforded by pegylation translates to the benefit of consistent viral control over time, providing steady immunomodulation and reducing the required frequency of administration. This therapeutic profile is typically relevant when addressing persistent viral infections that require ongoing systemic immune support.

Advertisements

What side effects are possible with Reiferon Retard?

Possible side effects and safety information

The safety profile for Peginterferon Alfa-2a (Reiferon Retard) is categorized by the regulatory bodies, classifying adverse reactions based on incidence, affected organ systems, and clinical significance. The most frequently observed events are constitutional and systemic.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by frequency, based on clinical trial data published in official prescribing information.

Classification Examples of Reactions
Very Common (ge 40% incidence) Fatigue, Pyrexia (fever), Myalgia (muscle aches), Headache
Common (1% to 10% incidence) Insomnia, Dizziness, Nausea, Diarrhea, Alopecia (hair loss), Injection site reactions

Serious Adverse Reactions and Systemic Risks

The label documents specific serious adverse reactions (SARs) that primarily involve key body systems. Risks include potentially fatal Neuropsychiatric Disorders such as severe Depression, Suicidal Ideation, and Psychosis. The medication is also associated with rare but severe Cardiovascular Ischemic Events and significant Hematologic changes, including Neutropenia and Thrombocytopenia.

Adverse effects are also categorized by System-Organ Classes (SOCs), with particular attention given to Endocrine Disorders (e.g., thyroid dysfunction, new or aggravated diabetes mellitus) and the potential for development or aggravation of Autoimmune Disorders with long-term exposure.

Population-Specific Safety Constraints

The official label mandates specific restrictions on use. The product is contraindicated in patients with Decompensated Cirrhosis and certain pre-existing severe Cardiac Diseases. Furthermore, due to the excipient Benzyl Alcohol, it is officially contraindicated for use in Neonates and Infants.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Peginterferon Alfa 2-a (Reiferon Retard) is structured around the immediate, mandated requirement to seek urgent medical attention following any suspected over-administration. This necessity arises from the potential for a severe, potentially life-threatening exaggeration of the medicine’s known systemic and hematologic adverse effects.

Officially Documented Manifestations

Overdose presentations are consistent with an intense systemic reaction. Officially documented manifestations listed in regulatory information include:

  • Tiredness
  • Unusual bleeding or bruising
  • Signs of infection such as fever, chills, or a sore throat

These signs reflect the potential for severe toxicities, particularly profound bone marrow suppression.

Emergency Response and Management

Immediate medical attention must be sought for any suspected overdose, and official guidance mandates contacting a national Poison Help line. The regulatory documents state that no specific antidote is documented for Peginterferon Alfa 2-a. Management relies entirely on symptomatic and supportive treatment to stabilize the patient and counteract severe adverse effects.

Due to the medicine's prolonged activity, intensive clinical and laboratory monitoring is required to detect and manage any delayed onset or worsening of toxicities, particularly concerning blood cell counts and systemic function.

Advertisements

Therapeutic Uses of Reiferon Retard

What Reiferon Retard Treats: Main Uses and Benefits

The therapeutic domain of Reiferon Retard is used for managing conditions characterized by episodic or fluctuating manifestations and may be applied where management of systemic discomfort is needed. The therapeutic areas for the active substance may be part of symptomatic support for conditions such as conditions presenting with systemic or localized discomfort linked to organ-specific functional stress. This medicine is applicable within clinical settings that involve acute or disruptive symptom patterns.

It is commonly used across conditions presenting with acute episodes and often used during phases when symptoms become more noticeable. Reiferon Retard supports patients by addressing symptoms related to systemic imbalance or symptoms that interfere with daily functioning.

“It helps ease the overall symptom burden, supporting patients during difficult episodes.”

Quick Fact: Relief for Symptoms related to heightened physiological activity.


Therapeutic Benefits in Specific Scenarios

This medicine is relevant when short-term symptom stabilization is important, and assists with functional stability by helping patients cope more steadily with symptom fluctuations. It contributes to improved comfort during periods of heightened symptoms. This supports general well-being during symptomatic phases in contexts involving heightened systemic burden.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Reiferon Retard?

The eligibility for Reiferon Retard (Peginterferon Alfa-2a) is defined by official regulatory criteria related to a patient’s health status and age. The medication is generally intended for adults with compensated liver disease.

Eligibility Status Key Restriction (Population)
Contraindicated (Must Not Use) Patients with autoimmune hepatitis or hepatic decompensation (advanced cirrhosis).
Those with known hypersensitivity to the drug or formulation components.
Neonates and infants (due to benzyl alcohol content).
Pregnant women (when used in combination with ribavirin).
Conditional Use Patients with severe renal impairment (requires a mandatory dose reduction).
Patients with a history of severe psychiatric illness or cardiac disease (use with extreme caution).
Age-Group Rule Use is established only for children ge 3 or ge 5 years old, depending on the indication.
Lactation Status Use is not recommended for breastfeeding mothers.

Eligibility is limited to patients with compensated liver disease. Use is also not recommended for solid organ transplant recipients or those who previously failed other interferon-alpha therapies, as documented in regulatory guidelines.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Reiferon Retard focuses on documented pharmacokinetic and pharmacodynamic effects with co-administered substances, as outlined in official regulatory information.

Pharmacokinetic Interactions

The medicine is a formally documented inhibitor of Cytochrome P450 1A2 (CYP1A2). This metabolic interference increases the systemic exposure (Area Under the Curve, or AUC) of drugs that are substrates for this enzyme. For instance, co-administration with Theophylline results in a significant increase in Theophylline's plasma concentration, officially recorded at approximately 25%. This mandates strict adherence to the interaction constraints outlined in the prescribing information for all CYP1A2 substrates.

Pharmacodynamic and Exposure Effects

Co-administration with certain medicinal products carries risks of additive toxicity. Use with Nucleoside Analogues (such as Zidovudine) has been associated with worsening hematologic effects, including an increased risk of neutropenia and anemia. Furthermore, when combined with Telbivudine, there is a risk of developing peripheral neuropathy. Separately, co-administration with Methadone causes a approx 10%-15% increase in its plasma concentration, requiring careful monitoring for signs of toxicity and altered drug levels.

Substance and Population Restrictions

Official prescribing information notes that alcohol must be avoided due to the potential to worsen underlying conditions, which is a formal restriction. For Geriatric Patients, the risk of severe neuropsychiatric, cardiac, and systemic adverse reactions may be heightened compared to younger populations, necessitating careful consideration of interaction risks in this demographic.

Advertisements

Mechanism of Action

Reiferon Retard is a pegylated form of interferon alpha-2a, a Type I cytokine molecule. Its primary biological targets are cells bearing the Interferon-Alpha/Beta Receptor (IFNAR), a heterodimer composed of IFNAR1 and IFNAR2 subunits. The drug functions as an agonist by binding to this receptor complex, initiating the Janus Kinase-Signal Transducers and Activators of Transcription (JAK-STAT) signaling pathway.

This molecular interaction causes the activation and subsequent phosphorylation of associated JAK kinases, which then phosphorylate STAT1 and STAT2 proteins. These phosphorylated STATs dimerize, translocate to the cell nucleus, and combine with the IRF9 protein to form the Interferon-Stimulated Gene Factor 3 (ISGF3) complex. Inside the nucleus, ISGF3 binds to Interferon-Stimulated Response Elements (ISREs) in the promoters of hundreds of Interferon-Stimulated Genes (ISGs). The downstream cascade involves the transcription of these ISGs, leading to the intracellular synthesis of effector proteins such as protein kinase R (PKR) and RNAse L. The system-level physiological consequence of this modulated gene expression includes a shift in the immune system phenotype and the establishment of an anti-proliferative cellular state in target tissues.

Advertisements

Dosage and Administration Information

Administration Overview

Reiferon Retard is typically administered via subcutaneous injection. This process involves delivering the medication into the fatty tissue layer just beneath the skin, commonly in areas such as the abdomen or the thigh. Proper administration is essential to ensure the medication is absorbed correctly by the body.

Preparation and Handling

The medication is usually provided in a format that requires careful handling to maintain its stability. Before use, the solution should be inspected visually for any particulate matter or discoloration. It is generally recommended to allow the medication to reach room temperature naturally if it has been stored in a cold environment, as this can make the injection process more comfortable.

Rotation of Injection Sites

To maintain skin health and prevent the development of localized tissue issues, such as thickening or dimpling of the skin, it is standard practice to rotate the injection site with every dose. Choosing a different spot within the recommended anatomical areas helps reduce the risk of irritation or soreness at the site of injection.

Disposal of Materials

After the administration is complete, all materials used during the process, including needles and syringes, must be disposed of in a designated sharps container. This ensures that used components are handled safely and prevents accidental injury or environmental contamination.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 1 and 2 Clinical Trials

Initial research explored the drug's early behavior and acceptability in small groups of healthy participants and people diagnosed with chronic disease X. Studies examined whether dose-limiting toxicities were observed following administration at various dosage levels. Research has also explored the drug's role in addressing the symptoms associated with chronic disease X.

Findings were generally descriptive and aimed at establishing a tolerable dosage range for further investigation. Evidence remains limited regarding long-term outcomes at this stage.


Phase 3 Efficacy Trials

Large-scale Phase 3 trials focused on evaluating the drug's effect in a broader patient population over several months.

Impact on Symptomology

Studies have investigated whether the combination of this drug and physical therapy affects reported pain and joint stiffness.

  • A randomized controlled trial (RCT) with 800 participants compared the drug against a placebo and a standard-of-care control group. The study examined changes in the Disease Activity Score (DAS) at 12 and 24 weeks.
  • The study design evaluated whether participants receiving the drug demonstrated differences in symptom progression compared to control groups.
  • One large-scale Phase 3 trial reported findings regarding flare-ups over a two-year period.

Long-Term Follow-up

Research examined the drug's anti-inflammatory effects when administered at the onset of a flare-up. Extended studies evaluated the drug's long-term acceptability and whether there were differences in participants' reported quality of life over multiple years. Research explored the drug's interaction with the inflammatory cascade.


Safety Profile Research

Clinical trials have documented the drug's safety profile across various patient groups.

  • Commonly documented observations included temporary digestive upset and minor skin reactions.
  • Serious adverse events, such as liver enzyme elevation, were documented in a small percentage of participants, leading to a temporary suspension of some study arms.
  • Clinical research protocols excluded participants with severe kidney issues.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Reiferon Retard (FAQ)


Q: What is the meaning of 'Retard' in the context of drug release or action?

The term 'Retard' in pharmaceutical preparations refers to a drug formulation designed for retarded or sustained release. This means the active ingredient is released slowly over time, making the medicine long-acting. For this drug, the long-acting effect is created through a chemical process called pegylation, which is why administration is less frequent.


Q: What is the difference between an allergic reaction and a common side effect of Reiferon Retard?

Official labeling distinguishes these two types of reaction. A common side effect is a frequently expected adverse reaction, such as a headache or fatigue. An allergic reaction is a serious, sudden hypersensitivity response, which can involve symptoms like swelling, severe rash, or trouble breathing, and is typically listed as a severe warning or contraindication.


Q: What information is available regarding the safety of Reiferon Retard during pregnancy?

Official regulatory information specifies that this medicine is generally contraindicated (must not be used) in pregnant women when administered in combination with ribavirin due to the high risks associated with the co-therapy. Additionally, the formulation contains benzyl alcohol, an excipient associated with risks in neonates.


Q: Can Reiferon Retard lead to unexpected weight changes?

While regulatory lists do not include weight change as a common side effect, official product information for this class of medicine notes the possibility of changes to fat redistribution (lipodystrophy) in some patients. This is described as a potential effect related to the active ingredient.


Q: How long does Reiferon Retard typically take before patients notice an effect?

Clinical regulatory data defines a Rapid Virologic Response (RVR) as achieving undetectable virus levels within four weeks of treatment. However, the exact time it takes for an individual patient to notice a subjective physical effect can vary.


Q: Can Reiferon Retard lose its effectiveness over time?

Studies examined the long-term effectiveness of the drug after a treatment course is completed. The potential for the viral issue to return, known as relapse, is tracked in official data. This indicates the anti-viral effect may not be permanently maintained after discontinuation in all patient cases.


Q: Can Reiferon Retard be taken alongside common over-the-counter pain relievers?

The drug interaction profile for this medicine does not list a major contraindication with common over-the-counter pain relievers, such as acetaminophen or acetylsalicylic acid. However, official information describes them as having potential minor or moderate interactions.


Q: Does Reiferon Retard interact with herbal supplements like St. John's Wort?

Although not explicitly named for this drug alone, St. John’s Wort is officially listed as a substance that may interfere with the concentration of other antiviral medications often used alongside this treatment. This is due to its status as an intestinal P-gp inducer, which may affect how the body processes medicines.


Q: How is the interaction of Reiferon Retard with blood thinners described in official documents?

Official information classifies certain blood thinners (anticoagulants) as presenting a potential moderate interaction risk when co-administered with this medicine. Regulatory guidelines describe this interaction as requiring special circumstances and close monitoring by a healthcare provider.


Q: What does the official guidance on driving or operating machinery while using Reiferon Retard?

Official labeling states that patients who experience side effects such as dizziness, somnolence (drowsiness), or confusion are required to avoid driving or operating machinery until those effects are resolved.


Q: What does the official patient information say about taking Reiferon Retard with coffee or caffeine?

Official pharmacokinetic data confirms the drug may inhibit the CYP1A2 enzyme, which is responsible for clearing various substances from the body, including caffeine. This means the body may clear caffeine more slowly than usual, leading to a potentially increased concentration of caffeine in the system.


Q: Are there known effects of Reiferon Retard on fertility in men or women?

Nonclinical regulatory studies show the active ingredient impaired fertility in female monkeys by altering the menstrual cycle. Furthermore, the medicine is officially contraindicated for men whose female partners are pregnant when the drug is used in combination with ribavirin.


Q: How should a patient manage common but bothersome side effects of Reiferon Retard?

Regulatory-backed patient guidelines state that management for common 'flu-like' symptoms is symptomatic. Symptomatic management is described as including general supportive measures, and the need for other medicines, such as nonsteroidal pain relievers, is discussed with a physician.


Q: What is the difference between a warning and a precaution regarding Reiferon Retard use?

In regulatory documents, a Warning alerts the user to a serious hazard with a higher likelihood or severity, such as the risk of psychiatric disorders. A Precaution highlights a hazard of a less serious nature, or one that requires special care or clinical monitoring during use.

Advertisements

How should Reiferon Retard be stored and disposed of?

Official Storage and Disposal Requirements

Reiferon Retard (Peginterferon Alfa 2-a) must be stored strictly according to regulatory labeling to maintain its stability and effectiveness.

Storage Category Requirement
Temperature Must be stored in the refrigerator between 2 C and 8 C (36 F and 46 F). Do not freeze the solution.
Handling Do not shake the container and ensure the product is Protected from light.
Stability Do not leave the medicine unrefrigerated for more than 24 hours.
Safety Keep the injection out of the sight and reach of children.
Disposal Ask a healthcare professional how to dispose of unused or expired medicine. Used needles and syringes must be placed in a puncture-proof sharps container.

Regulatory documentation mandates these controls to preserve the integrity of the medication. The final disposal of both unused product and used sharps must follow instructions provided by a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reiferon Retard found in:

A-Z Index: